Form 4: Corcoran Acquires Verrica Pharmaceuticals Stock Options

Gavin Corcoran, a Director at Verrica Pharmaceuticals Inc., acquired stock options for 16,000 shares.

Summary

• Gavin Corcoran, a Director at Verrica Pharmaceuticals Inc. (VRCA), acquired 16,000 stock options.
• The stock options have an exercise price of $6.04 and an expiration date of June 4, 2036.
• These options are set to vest in 12 equal monthly installments starting July 5, 2026, and will be fully vested by the next annual stockholder meeting, contingent on continued service as a director.
• The transaction was reported on June 9, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common compensation practice and does not inherently signal positive or negative company performance.

Positives

• Director Gavin Corcoran has acquired a significant number of stock options, indicating a commitment to the company's future performance.
• The stock options provide a clear path to potential equity ownership, aligning management interests with shareholders.

Risks

• The vesting schedule for the stock options is contingent on continued service as a director, implying a risk of forfeiture if service is terminated before vesting.
• The value of the stock options is directly tied to the future performance of Verrica Pharmaceuticals' stock price.

Future Outlook

The stock options are subject to a vesting schedule that extends over 12 months, with full vesting anticipated by the next annual stockholder meeting, provided the director continues their service.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the pharmaceutical industry to incentivize long-term performance and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of stock options by a director aligns their interests with shareholders, potentially leading to decisions that enhance shareholder value.
• Employees: While not directly impacted, this type of compensation for directors can reflect the company's overall compensation philosophy.
• Management: The director's compensation is tied to company performance, incentivizing effective leadership.

Next Steps

• The stock options will vest in 12 equal monthly installments starting July 5, 2026.
• The options will be fully vested on the date of the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Verrica Pharmaceuticals, VRCA, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity